The first 1000 doses of the vaccine against the coronavirus will be produced in the laboratories of the IRBM group in Pomezia and then they will start with clinical trials.
The vaccine for the novel coronavirus is going to be produced in Italy. Oxford University will transfer its vaccine “seed stock” to ADVENT, the GMP-certified Contract Development and Manufacturing Organization of IRBM Group. Then testing can begin.
Dr. Piero Di Lorenzo, President and CEO of IRBM and CEO of Advent, expresses his enthusiasm:
“We are thrilled to be working with the Jenner Institute on this critical project […].Once again IRBM Group is at the forefront of R&D […]”
And Prof. Sarah Gilbert of the Jenner Institute says: “We are able to shorten the needed time for clinical test […]. The partnership with Advent will enable us to achieve our goal as quickly as possible”.
Article by Jacopo Bongini published on Notizie.it – 07/02/2020
Read the original article on Notizie.it